The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
blood plasma
circulating miRNA
early mortality
hematological malignancies
molecular biomarker
multiparametric model
multiple myeloma
prognosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
05
12
2022
revised:
28
01
2023
accepted:
31
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first year of diagnosis. Numerous studies investigating microRNA (miRNA) expression patterns suggest they may be good prognostic markers. The primary aim of this study was to analyze the expression of selected miRNAs in the serum of MM patients who were later treated with bortezomib-based regimens, and to determine their potential to predict early mortality. The study was conducted in 70 prospectively recruited patients with newly diagnosed MM admitted to the Department of Hematology of the Copernicus Memorial Hospital, Lodz (Poland) between 2017 and 2021. Among them, 17 patients experienced death within 12 months of diagnosis. The expression of 31 selected miRNAs was determined using a miRCURY LNA miRNA Custom PCR Panel. The obtained clinical data included patient characteristics on diagnosis, treatment regimen, response to treatment, and follow-up. Differential expression analysis found two miRNAs to be significantly downregulated in the early mortality group: hsa-miR-328-3p (fold change-FC: 0.72,
Identifiants
pubmed: 36769265
pii: ijms24032938
doi: 10.3390/ijms24032938
pmc: PMC9917942
pii:
doi:
Substances chimiques
Bortezomib
69G8BD63PP
MicroRNAs
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Cancer Center
ID : NCN (2016/23/B/NZ5/02529
Pays : Republic of Korea
Références
Medicine (Baltimore). 2019 Aug;98(33):e16711
pubmed: 31415363
N Engl J Med. 2008 Aug 28;359(9):906-17
pubmed: 18753647
Clin Exp Pharmacol Physiol. 2020 Mar;47(3):485-494
pubmed: 31793036
Lancet. 2006 Mar 11;367(9513):825-31
pubmed: 16530576
Hematology. 2016 Aug;21(7):392-8
pubmed: 26868131
Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e449-e455
pubmed: 33485835
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1730-1737
pubmed: 33285523
Int J Cancer. 2015 Apr 15;136(8):1835-44
pubmed: 25220540
Lancet Oncol. 2010 Oct;11(10):934-41
pubmed: 20739218
Am J Hematol. 2015 Apr;90(4):E73-4
pubmed: 25561348
Leukemia. 2017 Sep;31(9):1915-1921
pubmed: 28008176
Recent Results Cancer Res. 2011;183:25-35
pubmed: 21509679
World J Clin Cases. 2022 Jun 6;10(16):5165-5184
pubmed: 35812667
Drugs R D. 2019 Jun;19(2):73-92
pubmed: 30993606
Cancer Lett. 2012 Jul 28;320(2):189-97
pubmed: 22388101
Pol Arch Intern Med. 2021 Jun 29;131(6):527-534
pubmed: 33908731
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Oncogene. 2015 May 21;34(21):2690-9
pubmed: 25065597
Mol Pharmacol. 2009 Jun;75(6):1374-9
pubmed: 19270061
Cancers (Basel). 2019 Nov 06;11(11):
pubmed: 31698726
Cancer Res. 2019 May 1;79(9):2314-2326
pubmed: 30894370
Haematologica. 2012 Aug;97(8):1272-7
pubmed: 22371180
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Oncogene. 2012 Oct 18;31(42):4509-16
pubmed: 22179828
Mol Cells. 2013 Jul;36(1):62-8
pubmed: 23820886
Curr Med Chem. 2021 Oct 25;28(33):6753-6772
pubmed: 33949926
Blood. 2010 Dec 23;116(26):5838-41
pubmed: 20876454
Methods. 2013 Jan;59(1):S1-6
pubmed: 23036329
J Clin Oncol. 2005 Dec 20;23(36):9219-26
pubmed: 16275935
Oncol Lett. 2018 Sep;16(3):4001-4007
pubmed: 30128020
Front Pharmacol. 2019 Feb 21;10:137
pubmed: 30846940
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
J Transl Med. 2015 Jun 18;13:195
pubmed: 26084278
Blood. 2017 Apr 27;129(17):2429-2436
pubmed: 28213378
Cell Physiol Biochem. 2014;34(4):1273-90
pubmed: 25278243
J Cancer. 2021 Sep 9;12(21):6519-6530
pubmed: 34659543
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32916955
Lancet Oncol. 2010 Jan;11(1):29-37
pubmed: 19853510
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Lancet. 2007 Oct 6;370(9594):1209-18
pubmed: 17920916
Ann Hematol. 2001 Aug;80(8):452-5
pubmed: 11563589
Br J Cancer. 2012 Mar 27;106(7):1320-30
pubmed: 22453125
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
IUBMB Life. 2016 May;68(5):394-402
pubmed: 27079864
Antiviral Res. 2019 Mar;163:185-192
pubmed: 30711417
Med Sci Monit. 2010 Oct;16(10):HY27-30
pubmed: 20885358
Int J Mol Med. 2016 Apr;37(4):1030-8
pubmed: 26935807
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Medicine (Baltimore). 2015 Dec;94(50):e2305
pubmed: 26683968
Am J Hematol. 2016 Jul;91(7):700-4
pubmed: 27074204
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Cancers (Basel). 2021 Jul 31;13(15):
pubmed: 34359778
Ann Oncol. 2014 Jan;25(1):195-200
pubmed: 24356630
J Clin Oncol. 2008 May 1;26(13):2171-7
pubmed: 18362366
Leukemia. 2015 Jul;29(7):1616-8
pubmed: 25673239